FDA Approves Joenja for Children 4–11 with APDS, First U.S. Pediatric Treatment
PHAR sits 16% above its 52-week low of $9.62 on elevated volume (2.6× avg).
Summary
FDA approved Joenja for children aged 4 to 11 weighing at least 27 kg with APDS, making it the first U.S. treatment for this pediatric group. New doses are expected to be available in October.
Key Events · Product Development and Regulatory · PHAR
-
FDA Approves Pediatric Joenja Label
FDA approved 40 mg and 50 mg twice-daily Joenja dosing for children aged 4 to 11 weighing at least 27 kg with APDS, making it the first U.S. treatment for this age group.
-
Commercial Launch Expected October
The newly approved pediatric doses are expected to be available to eligible U.S. patients in October 2026 through Pharming's existing specialty distribution network.
-
Separate sNDA for Younger Patients Pending
On July 30, Pharming submitted a separate sNDA for lower Joenja doses for pediatric APDS patients aged 4 to 11 weighing 13 kg to less than 27 kg, still under FDA review.
-
Label Expansion Broadens Addressable Market
Joenja was previously approved only for patients 12 and older; this approval extends the franchise to younger children, expanding the commercial opportunity for Pharming's key growth product.
Analysis · PHAR · Life Sciences
Joenja becomes the first FDA-approved treatment for children aged 4 to 11 with APDS in the U.S., expanding the label from the prior 12-and-older indication. The approval adds a new pediatric patient population to the commercial franchise, with the new doses expected to reach the market in October. This follows the July 30 guidance cut and a separate sNDA for even younger, lower-weight patients still under review — together broadening the addressable market for the company's key growth product.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.4% of the 1487 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAR was trading at $11.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $759.5M. The 52-week trading range was $9.62 to $21.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.